220 related articles for article (PubMed ID: 38414439)
1. Impact of antifibrotic therapy on disease progression, all-cause mortality, and risk of acute exacerbation in non-IPF fibrosing interstitial lung diseases: evidence from a meta-analysis of randomized controlled trials and prospective controlled studies.
Li DY; Liu X; Huang JY; Hang WL; Yu GR; Xu Y
Ther Adv Respir Dis; 2024; 18():17534666241232561. PubMed ID: 38414439
[TBL] [Abstract][Full Text] [Related]
2. Possible value of antifibrotic drugs in patients with progressive fibrosing non-IPF interstitial lung diseases.
Torrisi SE; Kahn N; Wälscher J; Sarmand N; Polke M; Lars K; Eichinger M; Heussel CP; Palmucci S; Sambataro FM; Sambataro G; Sambataro D; Vancheri C; Kreuter M
BMC Pulm Med; 2019 Nov; 19(1):213. PubMed ID: 31718637
[TBL] [Abstract][Full Text] [Related]
3. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
Lamb YN
Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
[TBL] [Abstract][Full Text] [Related]
4. Impact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.
Petnak T; Lertjitbanjong P; Thongprayoon C; Moua T
Chest; 2021 Nov; 160(5):1751-1763. PubMed ID: 34217681
[TBL] [Abstract][Full Text] [Related]
5. Progressive fibrosing interstitial lung diseases: A new concept and indication of nintedanib.
Makino S
Mod Rheumatol; 2021 Jan; 31(1):13-19. PubMed ID: 32964766
[TBL] [Abstract][Full Text] [Related]
6. Nationwide epidemiologic study for fibrosing interstitial lung disease (F-ILD) in South Korea: a population-based study.
Joung KI; Park H; Park S; Shin JY; Kim YH
BMC Pulm Med; 2023 Mar; 23(1):98. PubMed ID: 36949407
[TBL] [Abstract][Full Text] [Related]
7. [Use of antifibrotic drugs in interstitial lung disease].
Kreutz CP; Gesierich W; Behr J; Kneidinger N
Dtsch Med Wochenschr; 2022 Oct; 147(21):1383-1390. PubMed ID: 36279864
[TBL] [Abstract][Full Text] [Related]
8. Advances in Targeted Therapy for Progressive Fibrosing Interstitial Lung Disease.
Gibson CD; Kugler MC; Deshwal H; Munger JS; Condos R
Lung; 2020 Aug; 198(4):597-608. PubMed ID: 32591895
[TBL] [Abstract][Full Text] [Related]
9. Exposure-efficacy analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
Schmid U; Weber B; Magnusson MO; Freiwald M
Respir Med; 2021; 180():106369. PubMed ID: 33798871
[TBL] [Abstract][Full Text] [Related]
10. Exposure-safety analyses of nintedanib in patients with chronic fibrosing interstitial lung disease.
Schmid U; Weber B; Sarr C; Freiwald M
BMC Pulm Med; 2021 Jul; 21(1):244. PubMed ID: 34289823
[TBL] [Abstract][Full Text] [Related]
11. Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Wells AU; Flaherty KR; Brown KK; Inoue Y; Devaraj A; Richeldi L; Moua T; Crestani B; Wuyts WA; Stowasser S; Quaresma M; Goeldner RG; Schlenker-Herceg R; Kolb M;
Lancet Respir Med; 2020 May; 8(5):453-460. PubMed ID: 32145830
[TBL] [Abstract][Full Text] [Related]
12. The extended utility of antifibrotic therapy in progressive fibrosing interstitial lung disease.
Sarkar P; Avram C; Chaudhuri N
Expert Rev Respir Med; 2020 Oct; 14(10):1001-1008. PubMed ID: 32567402
[TBL] [Abstract][Full Text] [Related]
13. Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases.
Wollin L; Distler JHW; Redente EF; Riches DWH; Stowasser S; Schlenker-Herceg R; Maher TM; Kolb M
Eur Respir J; 2019 Sep; 54(3):. PubMed ID: 31285305
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
Finnerty JP; Ponnuswamy A; Dutta P; Abdelaziz A; Kamil H
BMC Pulm Med; 2021 Dec; 21(1):411. PubMed ID: 34895203
[TBL] [Abstract][Full Text] [Related]
15. Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases.
Cottin V; Richeldi L; Rosas I; Otaola M; Song JW; Tomassetti S; Wijsenbeek M; Schmitz M; Coeck C; Stowasser S; Schlenker-Herceg R; Kolb M;
Respir Res; 2021 Mar; 22(1):84. PubMed ID: 33726766
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of antifibrotic agents in the treatment of CTD-ILD and RA-ILD: A systematic review and meta-analysis.
Yang M; Wu Y; Liu X; Zhao C; Li T; Li T; Zhang X; Jiang H; Mao B; Liu W
Respir Med; 2023 Sep; 216():107329. PubMed ID: 37315742
[TBL] [Abstract][Full Text] [Related]
17. Antifibrotic drugs as treatment of nonidiopathic pulmonary fibrosis interstitial pneumonias: the time is now (?).
Kreuter M; Wälscher J; Behr J
Curr Opin Pulm Med; 2017 Sep; 23(5):418-425. PubMed ID: 28622199
[TBL] [Abstract][Full Text] [Related]
18. Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.
Feng H; Zhao Y; Li Z; Kang J
Ther Adv Respir Dis; 2020; 14():1753466620963015. PubMed ID: 33070705
[TBL] [Abstract][Full Text] [Related]
19. Antifibrotic Therapies and Progressive Fibrosing Interstitial Lung Disease (PF-ILD): Building on INBUILD.
Shumar JN; Chandel A; King CS
J Clin Med; 2021 May; 10(11):. PubMed ID: 34070297
[TBL] [Abstract][Full Text] [Related]
20. Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study).
Nasser M; Larrieu S; Si-Mohamed S; Ahmad K; Boussel L; Brevet M; Chalabreysse L; Fabre C; Marque S; Revel D; Thivolet-Bejui F; Traclet J; Zeghmar S; Maucort-Boulch D; Cottin V
Eur Respir J; 2021 Feb; 57(2):. PubMed ID: 32943410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
